Insulins
High-yield High-alert Verified · Oct 2026Insulins are a class of medications used for type 1 diabetes mellitus.
Medical view → mechanisms, drug comparisons and Step 1 pharmacology
The fed-state hormone, given by injection. A high-alert medication: learn the onset/peak/duration profiles and the hypoglycemia response cold.
How it works in the body
The system involved, what goes wrong, and how the drug and body interact.
01 Glucose homeostasis — insulin is the body’s "storage" hormone
Blood glucose is governed by two opposing hormones from the pancreas. Insulin (from the beta cells) is the fed-state, anabolic hormone: after a meal, rising glucose triggers its release, and it moves that glucose out of the blood and into storage. Its counterpart, glucagon (from the alpha cells), does the opposite when glucose runs low — telling the liver to release stored sugar.
At the target tissues, insulin binds a receptor that triggers GLUT4 transporters to surface on muscle and fat cells, opening the door for glucose to enter. In the liver it shuts off glucose production (gluconeogenesis) and stores glucose as glycogen. It also builds fat and protein — and, importantly for the ward, it drives potassium into cells by stimulating the Na⁺/K⁺-ATPase. That last effect is why IV insulin (with dextrose) is a treatment for hyperkalemia — and why hypokalemia is a watch-point.
02 Type 1 vs type 2 — and why the profiles matter
In type 1 diabetes, an autoimmune attack destroys the beta cells, leaving an absolute insulin deficiency — these patients must have insulin to live. In type 2 diabetes, the tissues become resistant to insulin and beta-cell output slowly declines, a relative deficiency; insulin is added when other agents no longer keep up.
Because injected insulin has to mimic what a healthy pancreas does automatically, the different formulations are engineered to act over different time courses — and matching the right insulin to the right moment is central to safe dosing. Rapid-acting (lispro, aspart) covers a meal and is given right before eating. Short-acting regular insulin (U-100) is the classic IV insulin (DKA drips, hyperkalemia); the rapid analogs lispro (U-100) and aspart are also labeled for IV infusion under supervision, but NPH and basal insulins are never given IV. Intermediate NPH is a cloudy suspension that covers roughly half a day and has a distinct peak. Long-acting basal insulins (glargine, degludec) provide a flat, near-peakless background level over ~24 hours (detemir may be dosed twice daily). The concentrated glargine Toujeo (300 units/mL) may take about 5 days to reach its full glucose-lowering effect, and its first dose may not cover the first 24 hours, so glucose is checked daily when it is started.
03 Why the adverse effects follow — and the high-alert danger
Nearly every adverse effect is the therapeutic mechanism doing too much. Hypoglycemia — the number-one risk — is simply more insulin effect than the patient’s food and activity call for; it is most likely at each insulin’s peak, which is why knowing the profiles is a safety skill, not trivia. The same potassium shift that treats hyperkalemia can cause hypokalemia (critical in DKA). The anabolic effect brings weight gain, and repeatedly injecting the same spot causes lipohypertrophy — lumpy tissue that absorbs insulin erratically, so sites are rotated.
Insulin has no traditional boxed warning, yet it is one of the most common high-alert medications, because a dosing error can be life-threatening. The classic errors are mix-ups (rapid vs. long-acting, U-100 vs. U-500), misread orders (error-prone abbreviations — "units" is always written out), and giving mealtime insulin to a patient who then doesn’t eat. This is why insulin doses get an independent double-check, are drawn only in insulin-specific syringes, and are never given without confirming the patient will eat.
Drug names
Indications
- Type 1 diabetes mellitus — required, lifelong (absolute deficiency)
- Type 2 diabetes when diet, lifestyle, and other agents are inadequate; gestational diabetes
- DKA and HHS (IV regular U-100 insulin; basal glargine and degludec labels say they are not recommended for treating DKA); hyperkalemia (IV regular U-100 insulin + dextrose)
Mechanism of action
Exogenous insulin binds the insulin-receptor tyrosine kinase, triggering GLUT4-mediated glucose uptake into skeletal muscle and fat, suppressing hepatic glucose production, and promoting glycogen, fat, and protein synthesis. It also drives potassium intracellularly via the Na⁺/K⁺-ATPase — lowering both blood glucose and serum potassium.
Therapeutic effects — what you'll see working
Success is glucose brought into range without causing lows. Track it with fingersticks (or CGM) timed to meals and insulin peaks, and with the A1c — the roughly 3-month average. Individualize goals, and never apply standard adult targets to a pregnant patient.
- ↓ Blood glucose
- Glucose is pulled into cells and hepatic output is suppressed. Judge by fingerstick/CGM timed to meals and to each insulin’s peak; targets are individualized with the care team; for most non-pregnant adults, CDC lists 80–130 mg/dL before meals and below 180 mg/dL 1–2 hours after meals.
- A1c to goal
- The glycated-hemoglobin level reflects the ~3-month average glucose. A common general goal is < 7%, individualized — higher (7 to 8% or more) for people with limited life expectancy, severe hypoglycemia or hypoglycemia unawareness, or advanced complications (NIDDK). It lets the insulin dose be adjusted to the past three months of control.
- K⁺ lowered (hyperkalemia use)
- Given IV with dextrose, regular (U-100) insulin shifts potassium into cells — a temporizing treatment for hyperkalemia while the underlying cause is addressed. The mirror image of this effect is the hypokalemia to watch for.
Adverse effects
Read the adverse effects as “too much insulin effect” (hypoglycemia, the K⁺ shift) plus the consequences of daily injection. There is no boxed warning — the danger is dosing error, which is why insulin is treated as high-alert.
Antidote
Interactions
Contraindications
Insulin’s labeled contraindications are use during an episode of hypoglycemia and hypersensitivity to the product or an excipient; otherwise the dose is adjusted (for example, in renal or hepatic impairment) rather than withheld.
When to hold
Assess before giving — these findings mean hold the dose and act.
Labs & levels
Nursing considerations
The RN-specific layer — each action paired with the reason it matters.
Common questions
What are Insulins used for?
How do Insulins work?
What are the serious side effects of Insulins?
What is the antidote for Insulins toxicity?
When should a nurse hold Insulins, and what safety checks apply?
What labs should be monitored with Insulins?
Conditions treated
CF-related diabetes. StatPearls (CFRD): "Insulin is the preferred treatment for individuals with cystic fibrosis-related diabetes. Insulin therapy has been associated with better glycemic control, improved weight gain, and improved pulmonary function in CFRD." StatPearls, citing ISPAD: "There is currently insufficient data to recommend non-insulin injectables or oral hypoglycemic agents in CFRD. Prescribing these medications should not take place in this population outside of clinical trials."
In type 1, insulin is not one option among several — β-cell function is absent, so lifelong replacement (pump or basal-bolus multiple daily doses) is required, and stopping it invites DKA. In type 2, insulin enters when hyperglycemia is severe or symptomatic — A1C > 10%, glucose ≥ 300 mg/dL (ADA 2026), or catabolic weight loss/ketosis. Insulin is also a leading hypoglycemia culprit: every patient on it gets the 15-15 rule and, ideally, prescribed glucagon.
IV regular insulin by continuous infusion (0.1 U/kg/h) is the mainstay of DKA treatment: it restores glucose uptake and shuts off gluconeogenesis and glycogenolysis — and, by correcting the deficiency itself, stops the lipolysis-to-ketone cascade producing the acid. Its short action (onset ≈ 1 h, IV-titratable, duration ≈ 4 h) is exactly what an hourly-titrated drip needs. Demands close glucose and potassium monitoring — see the sequence.
Glycemic control prevents and slows DR. NEI: keep blood sugar in range by "carefully following your doctor’s instructions for your insulin or other diabetes medicines." "The initial stages of diabetic retinopathy are reversible if proper glycemic control is achieved" (StatPearls). When glycemic control is intensified quickly, early worsening of retinopathy has an association with "the amplitude of HbA1c reduction" (systematic review) — a reason for eye checks, not for loosening control.
The preferred pharmacologic agent in gestational diabetes, and the reason is placental: insulin does not cross to the fetus. ADA 2026 states it plainly — insulin is the preferred drug for GDM — and the mechanism makes the preference obvious. Everything that crosses the placenta reaches a fetus whose own pancreas is already over-secreting insulin because of maternal glucose it cannot refuse; an agent that stays on the maternal side lowers maternal glucose without adding a fetal drug exposure. The regimen has a shape dictated by the targets: a basal component for the fasting number, which is placental-resistance driven and worst in the morning, and a short-acting component for the 1- and 2-hour postprandial numbers. Two disorder-side facts change nursing practice. First, the requirement climbs through gestation because placental hormone output rises with placental mass, so dosing is recalculated rather than fixed, and a dose increase is expected physiology rather than patient failure. Second, the requirement falls the moment the placenta is delivered — ADA 2026 advises reassessing and adjusting insulin after delivery because insulin resistance drops sharply right after birth. Units, titration algorithms, onset and duration profiles and hypoglycemia treatment belong to the class page.
Deliberately second — and at half the DKA rate: a fixed-rate IV infusion of 0.05 units/kg/h, started only after fluid resuscitation is underway and K⁺ > 3.5 mmol/L (some recommend waiting until glucose has stopped dropping on fluids alone; immediately only if significant ketonemia = mixed picture, then the DKA rate of 0.1). Rationale: fluids are already lowering the glucose, and a rapid osmolar drop risks cerebral edema. When glucose reaches < 250 mg/dL, dextrose 5–10% is added and glucose is held at 200–250 until resolution. Patients on basal insulin may continue their usual dose alongside the infusion to reduce rebound hyperglycemia.
New diabetes. Diabetes can be a presenting sign (new-onset diabetes without risk factors) and "develops in approximately 20% of patients postoperatively" after a Whipple. The perioperative bundle includes "Ensuring normothermia and euglycemia." The sources give no insulin regimen — role only.
See also
Non-insulin agents for type 2 diabetes — each subclass targets a different broken "lever." Metformin is first-line.
Four smaller groups of type 2 diabetes drugs, each with its own lever: pioglitazone sensitizes tissues to insulin, acarbose and miglitol slow carbohydrate digestion in the gut, repaglinide and nateglinide give a short burst of insulin at meals, and pramlintide adds amylin alongside mealtime insulin. Their signature risks follow the lever: fluid retention and heart failure, gas and diarrhea, hypoglycemia with skipped meals, and severe hypoglycemia with insulin.
Glucagon is the rescue drug for severe hypoglycemia when the patient cannot safely take sugar by mouth; dasiglucagon, a glucagon analog, is used the same way. Given by injection or as a nasal powder, glucagon makes the liver release glucose from glycogen — so it works only if the liver has glycogen to give. It also relaxes the gut and is used as a diagnostic aid in radiology.
Replace thyroid hormone in hypothyroidism, or block its synthesis — or destroy the gland with radioactive iodine — in hyperthyroidism. TSH is the monitoring dial.
Powerful anti-inflammatory/immunosuppressive hormones. Never stop abruptly after prolonged use — taper.
Fludrocortisone replaces the missing mineralocorticoid in primary adrenal insufficiency, so it retains sodium and loses potassium — watch blood pressure, swelling and potassium. Osilodrostat and metyrapone block the last step of cortisol synthesis, and mifepristone (Korlym) blocks cortisol at its receptor; all three can tip a patient into adrenal insufficiency.
Sources
- Humulin R (regular insulin) — MOA, indications, hypokalemia & hypoglycemia (FDA label) — FDA / DailyMed
- Insulin — pharmacokinetics by class, adverse effects, contraindications — StatPearls (NCBI)
- Open RN Nursing Skills — Ch. 15 Administering Medications (high-alert double-check, "Do Not Use" abbreviations) — Open RN (NCBI Bookshelf)
- The A1C Test & Diabetes — individualized A1C goals — NIDDK (National Institutes of Health)
- HUMALOG (insulin lispro) — subcutaneous or IV use (FDA label) — DailyMed (NLM)
- NOVOLOG (insulin aspart) — time-action, IV use (FDA label) — DailyMed (NLM)
- HUMULIN N (NPH) — resuspension, mixing, not IV (FDA label) — DailyMed (NLM)
- NOVOLIN R (regular insulin) — FDA label — DailyMed (NLM)
- NOVOLIN N (NPH) — FDA label — DailyMed (NLM)
- LANTUS (insulin glargine) — no pronounced peak, not IV (FDA label) — DailyMed (NLM)
- TOUJEO (insulin glargine 300 units/mL) — FDA label — DailyMed (NLM)
- BASAGLAR (insulin glargine) — FDA label — DailyMed (NLM)
- TRESIBA (insulin degludec) — FDA label — DailyMed (NLM)
- HUMULIN R U-500 — concentrated insulin, dosing-error safeguards (FDA label) — DailyMed (NLM)
- LEVEMIR (insulin detemir) — do not mix (A-S Medication relabel; no current Novo Nordisk SPL) — DailyMed (NLM)
- Low Blood Glucose (Hypoglycemia) — treatment steps, glucagon — NIDDK (National Institutes of Health)
- Plasma Glucose — insulin, GLUT4, alpha and beta cells — StatPearls (NCBI)
- Diabetes — beta cells and alpha cells — StatPearls (NCBI)
- Insulin Lispro — sodium-potassium ATPase — StatPearls (NCBI)
- Adult Diabetic Ketoacidosis — precipitating factors — StatPearls (NCBI)
- Indian Injection Technique Study — absorption by injection site (2017) — PMC (open access)
- EADSG Guidelines — insulin storage and injection technique (2019) — PMC (open access)
- Beta-blockers mask hypoglycemia signs except sweating — case report (2019) — PMC (open access)
- High-risk abbreviations including ‘U for units’ — pharmacist-led intervention — PMC (open access)
- CDC — Monitoring Your Blood Sugar (target ranges) — Centers for Disease Control and Prevention
- Open RN Nursing Pharmacology — Ch. 9 Endocrine (hypoglycemia protocols: dextrose 50% IV or glucagon) — Open RN (NCBI Bookshelf)
- Selective Beta-1 Blockers — masking of hypoglycemia tachycardia and tremor; sweating persists — StatPearls (NCBI)
Reviewed by Hae Suk Lee, RN
Educational summary for nursing students. Always verify against current prescribing information and your institution's protocols before administering. Not medical advice.